Bra podd

Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleeding

7 augusti | 15 min

Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia

31 juli | 19 min

A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse

24 juli | 19 min

Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor

21 juli | 19 min

Review series on mantle cell lymphoma

17 juli | 17 min

Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas

10 juli | 20 min

A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes

3 juli | 19 min

An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM

26 juni | 18 min

Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in a

23 juni | 20 min

Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets

19 juni | 41 min

A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset

12 juni | 21 min

Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

10 juni | 10 min

How I Treat Series on Geriatric Hematology

5 juni | 17 min

Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance

5 juni | 16 min

New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE

29 maj | 20 min

How I Treat Transfusion Medicine (part 2)

22 maj | 34 min

Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma

22 maj | 21 min

How I Treat Transfusion Medicine (part 1)

15 maj | 32 min

Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT

15 maj | 18 min

Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease

8 maj | 20 min

Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature

1 maj | 18 min

Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy

24 april | 19 min

How I Treat Myeloproliferative Neoplasms

17 april | 39 min

The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL

17 april | 19 min

Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma

10 april | 21 min

Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL

3 april | 15 min

Blood Bonus Episode: What is a Blood group?

31 mars | 15 min

Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait

27 mars | 19 min

Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis

20 mars | 19 min

Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL

13 mars | 21 min

Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk

6 mars | 18 min

Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal antibodies

27 februari | 19 min

Review Series on a Quarter Century of TKIs in CML

27 februari | 33 min

A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes

21 februari | 19 min

Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

13 februari | 23 min

Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor

13 februari | 32 min

Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor

6 februari | 19 min

First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia

30 januari | 21 min

Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex

23 januari | 19 min

Review Series on Globin Disorders

23 januari | 23 min

Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma

16 januari | 22 min

Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk

9 januari | 17 min

Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

2 januari | 20 min

Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

26 december 2024 | 19 min

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

19 december 2024 | 20 min

Unravelling follicular lymphoma subtypes; stroke rate trends in sickle cell disease; procoagulant platelet activation promotes venous thrombosis

12 december 2024 | 19 min

Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma

5 december 2024 | 20 min

Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH

28 november 2024 | 19 min

Review Series on T-Cell Lymphoma

21 november 2024 | 33 min

Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets

21 november 2024 | 18 min

Exploring the ecosystem of extramedullary myeloma; role of ruxolitinib for pediatric acute GvHD; “YAP”-ing about YAP1 and thrombopoiesis in ITP

14 november 2024 | 19 min

First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia

7 november 2024 | 21 min

Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML

31 oktober 2024 | 19 min

Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis

24 oktober 2024 | 21 min

Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia

17 oktober 2024 | 19 min

Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS

10 oktober 2024 | 22 min

A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT

3 oktober 2024 | 19 min

Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis

26 september 2024 | 23 min

Transplant outcomes in pediatric Fanconi anemia; hepatic Foxo1 regulates iron homeostasis; clinical networks improve APL outcomes in Latin America

19 september 2024 | 19 min

CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and NPM1-altered leukemias

12 september 2024 | 23 min

TCR-T cells for post-HCT leukemia recurrence; platelets are the predominant source of procoagulant membranes in hemostasis; BR + R maintenance for MCL

5 september 2024 | 18 min

Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors

29 augusti 2024 | 1 min

Review Series on Factor XI

29 augusti 2024 | 45 min

Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL

22 augusti 2024 | 17 min

Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML

15 augusti 2024 | 24 min

Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD

8 augusti 2024 | 17 min

Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity

1 augusti 2024 | 23 min

Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism

25 juli 2024 | 22 min

Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT

18 juli 2024 | 24 min

Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of <em>SOX11</em> expression to EBV-negative Burkitt lymphomas

11 juli 2024 | 20 min

Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome

4 juli 2024 | 23 min

Review Series on Oncogenic Signaling and Immune Evasion in Hematologic Malignancies

27 juni 2024 | 16 min

GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL

27 juni 2024 | 20 min

Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease

20 juni 2024 | 24 min

A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy

13 juni 2024 | 19 min

Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma

6 juni 2024 | 23 min

Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML

30 maj 2024 | 19 min

Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia

23 maj 2024 | 22 min

Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons

16 maj 2024 | 20 min

Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching

9 maj 2024 | 22 min

ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins

2 maj 2024 | 19 min

Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction of outcomes for high-count monoclonal B lymphocytosis

25 april 2024 | 24 min

Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?

18 april 2024 | 19 min

Jak2V617F clonal hematopoiesis promotes arterial thrombosis; Staphylococcus aureus infection in Sézary syndrome; clinical features of RAC2-related immunodeficiency

13 april 2024 | 26 min

Molecular mimicry in aplastic anemia; emicizumab prophylaxis in infants with hemophilia; hydroxyurea reduces infections in SCA

4 april 2024 | 20 min

Review Series on the Influence of the Tumor Microenvironment on the Pathogenesis of B-Cell Lymphomas

28 mars 2024 | 32 min

Free light chain mass spectrometry in diagnosis and monitoring of AL amyloidosis; T cells of AML patients in remission have distinct RNA signatures; and protective effect of ADAMTS13 in sickle cell mice depends on von Willebrand factor clearance

28 mars 2024 | 23 min

Eculizumab in transplant-associated thrombotic microangiopathy; reclassifying malignant monocytosis; targeting tissue factor in antiphospholipid syndrome

21 mars 2024 | 21 min

Identification of rare relapse-initiating stem cells post-transplantation; interferon α impairs erythropoiesis in sickle cell disease; TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis

14 mars 2024 | 23 min

How PAR2 signaling drives thrombo-inflammation; pretransfusion hemoglobin levels linked to survival in beta-thalassemia; etoposide is better than its reputation in primary HLH

7 mars 2024 | 18 min

Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss

29 februari 2024 | 23 min

CAR T cells plus ibrutinib in relapsed/refractory MCL; targeting SGF29 in AML; diffusion-limited oxygen release from stored blood

22 februari 2024 | 19 min

Long-term outcomes of pulmonary embolism in children and adolescents; hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens; predictors of loss of MRD negativity in multiple myeloma

15 februari 2024 | 25 min

Extended follow-up of axi-cel in indolent NHL; platelets help clear senescent RBCs; novel risk stratification strategy for CNS lymphoma

8 februari 2024 | 19 min

Lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma; reciprocal stabilization of coagulation factor XIII-A and -B subunits; inotuzumab ozogamicin for MRD in ALL

1 februari 2024 | 22 min

Maternal anticancer drug exposure and leukemia; PIEZO1-TMEM16F coupling in hereditary xerocytosis; NPM1 MRD during venetoclax therapy in NPM1-mutated AML

25 januari 2024 | 18 min

TCRαβ/CD19-cell depleted haploHSCT for pediatric leukemia; malignancy-associated hemophagocytic lymphohistiocytosis in Sweden; the bone marrow as the primary site of thrombopoiesis

18 januari 2024 | 22 min

Fibrin polymerization and thrombosis; preventing CD19-negative relapse after CAR T-cell therapy in ALL; and impact of aberrant FUS condensates on HSC aging

11 januari 2024 | 18 min

CD24Fc for prevention of GVHD; origins of active EBV disease; the role of PF4 in platelet activation

4 januari 2024 | 22 min

Profiling a new VITT-like disorder; real-world outcomes of tafasitamab and lenalidomide in LBCL; and spatial mapping of human hematopoiesis

28 december 2023 | 19 min

A natural history of familial platelet disorder with myeloid malignancy; HEXIM1 as an essential transcription regulator in erythropoiesis; residual disease predicts relapse in CML patients

21 december 2023 | 22 min

ETP and MRD for risk assessment in T-ALL; allogeneic HCT outcomes in CGD; effects of pathogenic/likely pathogenic variants in inherited hemostasis disorders

14 december 2023 | 20 min

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML; inhibition of PLK4 in TP53-mutated AML; the role of CD44 in Plasmodium falciparum infection

7 december 2023 | 23 min

High-risk cytogenetics in solitary bone plasmacytomas; complement activation in vaso-occlusive pain episodes; platelet reactivity to predict thrombotic disease risk

30 november 2023 | 19 min

Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibodies armed with B-BiTEs

23 november 2023 | 25 min

Fractionated gemtuzumab ozagamicin Dosing in Elderly AML Patients; Loss-of-function of ENT3 drives histiocytosis; Alternative splicing of CD20 5’-UTR in B-lymphomas

16 november 2023 | 20 min

Review Series on RNA Therapeutics in Hematology

14 november 2023 | 38 min

Prognostic significance of splicing factor gene mutations in AML; therapy resistance in multiple myeloma; the effects of KIT ligand deletion on HSC homeostasis

9 november 2023 | 20 min

Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging

2 november 2023 | 20 min

Lenalinomide plus rituximab for elderly patients with DLBCL, platelet GP6-mediated neutrophil recruitment in acute lung injury, and the role of AXL3 in mantle cell lymphoma.

26 oktober 2023 | 19 min

Gut microbiota diversity and mortality in pediatric allo-HSCT; C5 inhibition in atypical HUS; and pembrolizumab plus vorinostat in PD-1-refractory Hodgkin lymphoma

19 oktober 2023 | 20 min

IL-15 inhibitor BNZ-1 is safe and effective in T-cell LGLL, gene therapy trial for Wiskott-Aldrich syndrome, and ethical framework to select patients for CAR T-cell therapy

12 oktober 2023 | 23 min

DDX41 gene variant prevalence and AML/MDS risk, VITAL mAb treatment of light chain amyloidosis, and movement/neurocognitive toxicities after BCMA CAR T cell treatment

5 oktober 2023 | 19 min

IL-7 receptor signaling in B-cell differentiation, venetoclax plus obinutuzumab in older patients with CLL, LDL promotes microvascular thrombosis via von Willebrand Factor

28 september 2023 | 20 min

Real-world CAR T therapy in older DLBCL patients, monoclonal antibody blocking APC for hemophilia therapy, and targeting the epichaperome in AML

21 september 2023 | 18 min

Obinutuzumab, ibrutinib, and venetoclax in untreated CLL with deletion(17p)/TP53 mutation; NOTCH2 mutants promote chemo-resistance in DLBCL; and the role of DBY/HLA class II complexes in chronic GVHD

14 september 2023 | 22 min

Long-term outcomes with pembrolizumab in Hodgkin lymphoma, the “incredible ULK” alleviates β-thalassemia, and recommendations for managing CAR T hematotoxicity

7 september 2023 | 19 min

How I Manage Inpatient Consultations for Quantitative Neutrophil Abnormalities in Adults

31 augusti 2023 | 27 min

Dimethyl fumarate in cutaneous T-cell lymphoma, lipid nanoparticles for editing of human hematopoietic cells, and racial and geographic disparities in lymphoma trials

31 augusti 2023 | 24 min

Detailed safety profile of acalabrutinib vs ibrutinib in CLL, inflammation in trauma-induced coagulopathy, abatacept exposure and acute GVHD risk

24 augusti 2023 | 21 min

Pembrolizumab after ASCT in PTCL, germline predisposition to myeloid neoplasms in patients with hypoplastic bone marrow, and limited plasticity of monocyte fate and function

17 augusti 2023 | 21 min

Review Series on Hematopoietic Stem Cells

10 augusti 2023 | 18 min

WGS informs risk of follicular lymphoma transformation; resolvin D4 regulates neutrophil deployment; Hodgkin lymphoma-directed treatment for early-stage NLPHL

10 augusti 2023 | 21 min

Ventricular arrhythmias in sickle cell anemia, molecular heterogeneity of pediatric lymphoproliferative disorders, the role of the bone marrow microenvironment in myeloid disorders

3 augusti 2023 | 22 min

Silent infarcts in iTTP remission, a ZDHHC palmitoyltransferase regulates oxidative phosphorylation in AML, and hepatic sinusoid as a niche for ANKL

27 juli 2023 | 19 min

Poverty and relapse risk in children with ALL, eligibility and enrollment of diverse populations in myeloma trials, and clonal hematopoiesis in VEXAS syndrome

20 juli 2023 | 23 min

Pembrolizumab in PMBCL, allogeneic CD19 CAR T cells for pediatric B-cell ALL, and fetal iron overload in β-thalassemia

13 juli 2023 | 19 min

Gene therapy for WHIM syndrome, fate of hematopoietic stem cells after transplantation, and the role of C-terminal FGF23 peptides in iron conservation

6 juli 2023 | 20 min

Key role of hepcidin in polycythemia vera, signatures of CAR T cell dysfunction, and IL-34 as a novel AML therapy?

29 juni 2023 | 19 min

BMT as initial treatment for severe aplastic anemia, macrophage metabolic rewiring in sickle cell disease, and predicting outcomes using PET radiomics in diffuse large B cell lymphoma

22 juni 2023 | 19 min

End of the vincristine/steroid pulse era in pediatric ALL?, “trial and error” with abatacept in GVHD, and hemorrhage risk with dasatinib therapy

15 juni 2023 | 18 min

Prolonged response after stopping TPO-RA in ITP, TP53 mutations and myelofibrosis outcomes, clinical picture of ERCC6L2 disease, where variants predispose to marrow failure and malignancy

8 juni 2023 | 23 min

Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML

1 juni 2023 | 18 min

Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML

25 maj 2023 | 21 min

How I Treat Series: Emergent CAR T-Cell Toxicities

18 maj 2023 | 26 min

Specific CD8+ T cell clones in ITP, Refining DLBCL prognosis with the “dark-zone signature”, and rethinking the regenerative role of HSCs in acute hematopoietic emergencies

18 maj 2023 | 18 min

Tips for Trainees for a Career in Publishing with Drs. Nancy Berliner and Andrew Roberts

15 maj 2023 | 30 min

Axi-cel in refractory large B-cell lymphoma, effects of C1 inhibitor deficiency on coagulation, and the evolution of therapy-related myeloid neoplasms

11 maj 2023 | 19 min

Gut microbiota and outcomes in DLBCL, NFIA-ETO2 fusion cooperates with TP53 in leukemogenesis, and the impact of nirmatrelvir + ritonavir on CLL patient outcomes during the Omicron surge

4 maj 2023 | 19 min

Revised response criteria for high-risk MDS, machine learning guides diagnosis of bone marrow failure syndromes, and RhD-positive transfusions for Asian-type DEL patients with serologic RhD-negative typing

27 april 2023 | 22 min

AIHA during pregnancy, rapid immune tolerance induction in severe hemophilia A, and aging changes control of HSC proliferation

20 april 2023 | 17 min

Review Series on Classical Myeloproliferative Neoplasms

20 april 2023 | 23 min

Factor H variants in paroxysmal nocturnal hemoglobinuria, the role of factor XII in SCD-related thrombosis, and clinical features of therapy-related NPM1-mutated AML

14 april 2023 | 23 min

Lenalidomide and genetic profiling in myeloma, T-cell immunotherapy upregulates AML cell MHC-class II, and young fecal microbiota rejuvenate HSCs

6 april 2023 | 17 min

HLA-E-restricted immune response in EBV infection, the role of NRX-0492 in CLL, and NSAIDs for bone marrow failure in Ghosal Hematodiaphyseal Dysplasia

30 mars 2023 | 23 min

Review Series on Germ Line Predisposition to Hematologic Malignancy

30 mars 2023 | 33 min

Anti-malaria benefit of hydroxyurea in SCA, IL-22 in the treatment in lower GI acute GVHD, and FLT3-ITD changes depend on context in AML

23 mars 2023 | 18 min

Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma

16 mars 2023 | 21 min

RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL

9 mars 2023 | 17 min

Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia

2 mars 2023 | 22 min

Review Series on Banked Allogeneic Immune Effector Cells

23 februari 2023 | 22 min

Hydroxyurea for secondary stroke prevention in SCD, mutant CALR as a rogue cytokine in MPNs, and parsing pathobiology in Burkitt lymphoma

23 februari 2023 | 17 min

HSCT for hypomorphic RAG deficiency, EBV-driven lymphoid neoplasms in pediatric ALL, and clonal hematopoiesis and recurrent vascular events in stroke patients

16 februari 2023 | 20 min

MRD dynamics during ixazomib maintenance in MM, disparities in CAR T-cell therapy for ALL, and BAX variants and resistance to BH3-mimetics in AML

9 februari 2023 | 19 min

Itacitinib monotherapy for GVHD, the role of ERG in EVI1-driven AML, and germline DDX41 mutations in myeloid neoplasms

2 februari 2023 | 22 min

Review Series on Single-Cell Genomics

26 januari 2023 | 13 min

Stem cell transplant for SCD normalizes brain blood flow, novel GALE variants disrupt platelet development, and revisiting risk classification in NPM1-mutant AML

26 januari 2023 | 17 min

Allogeneic transplantation in older and infirm AML patients, cilta-cel in progressive multiple myeloma, and anti-CD20 therapy in relapsed TTP

19 januari 2023 | 21 min

Piezo antigens define a new blood group system, enasidenib in mutant-IDH2 relapsed/refractory AML, and breakthrough COVID-19 despite prophylaxis in B-cell malignancies

12 januari 2023 | 17 min

How I Treat Series: Management of High-risk Patients Following Allogeneic Transplant

5 januari 2023 | 21 min

Immune thrombocytopenia in pregnancy, ASCT in adults with inborn errors of immunity, and long-term health outcomes of childhood AML survivors

5 januari 2023 | 19 min

IL-13/IL-4 signaling and fibrotic progression in myelofibrosis, VWF-targeted thrombolysis in acute ischemic stroke, and NK cell dysfunction in relapsed AML

29 december 2022 | 16 min

Effects of iron repletion on donor RBC quality, long-term outcomes in relapsed/refractory hairy cell leukemia after vemurafenib, and off-the-shelf cryopreserved platelets for detecting HIT

22 december 2022 | 21 min

Germline predisposition variants occur in all age groups in MDS, αβ-haplo-HCT excels in children with acute leukemias/MDS, and poor outcomes after CAR T cell failure in B-cell lymphomas

15 december 2022 | 20 min

Predicting VTE in multiple myeloma, azithromycin promotes relapse after HSCT, and dual antigen targeted NK cells in B cell malignancies

8 december 2022 | 20 min

Using MRD to guide CLL treatment intensity, donor NK cells boost immune reconstitution after haplo-BMT, and EZH2 drives retinoic acid resistance in variant APL

1 december 2022 | 18 min

Tolerability of CD19 CAR T cells in lymphoma, causes of platelet spherocytosis, and using prebiotics to reduce GVHD

24 november 2022 | 20 min

Transplant in adult Ph+ ALL, acalabrutinib and ventricular arrythmias, and antibody prevention of fetal/neonatal alloimmune thrombocytopenia

17 november 2022 | 19 min

Restricting dietary methionine in AML, transferrin in high altitude-induced hypercoagulability, and LIF as protection against GVHD

10 november 2022 | 19 min

Sickle hemoglobin activates monocytes via TLR4, germinal center B cells provide a niche for T-cell lymphoma, and a combination immunosuppression regimen for acquired hemophilia A

3 november 2022 | 18 min

Lineage switching in MLL/AF4 leukemia, ibrutinib in mantle cell lymphoma with CNS relapse, and gilteritinib plus azacitidine in newly diagnosed FLT3-mutated AML

27 oktober 2022 | 23 min

Review Series on Megakaryopoiesis and Platelet Production

20 oktober 2022 | 22 min

Lenalidomide and subsequent TP53-mutated myeloid neoplasms, abnormal uterine bleeding after VTE, and novel tri-specific antibody for B-ALL

20 oktober 2022 | 18 min

Prognostic impact of NPM1 and FLT3 mutations in AML, progression of monoclonal B cell lymphocytosis, and creating RBCs with rare blood types in the laboratory

13 oktober 2022 | 21 min

Transplant outcomes in adults with immunodeficiencies and erythroblastic islands as niches for terminal erythropoiesis and granulopoiesis

7 oktober 2022 | 14 min

Ticagrelor in pediatric sickle cell disease, UBA1 translation impacts severity of VEXAS syndrome, and T-cell immunity and chemotherapy response in ALL

29 september 2022 | 22 min

Race affects treatment outcomes in iTTP, 2022 ELN AML recommendations, and a comprehensive MRD assessment in MCL

22 september 2022 | 20 min

The International Consensus Classification: An interview with Drs. Daniel Arber and Elias Campo

15 september 2022 | 19 min

Tranexamic acid prophylaxis in heme malignancies, N-glycosylation as a therapeutic vulnerability in CALR-mutant MPN, and myocardial fibrosis in sickle cell anemia

15 september 2022 | 21 min

Rest alleviates T-cell exhaustion by bispecific antibodies, exercise vs desmopressin in mild hemophilia A, and targeting MDM2 to enhance antileukemia immunity after transplant

8 september 2022 | 18 min

Sutimlimab vs placebo in cold agglutinin disease, the impact of etoposide versus auto-transplant in PTCL, and the role of pulmonary NETs in sickle cell disease

1 september 2022 | 21 min

Rivaroxaban after cancer surgery, genetics and survival in severe aplastic anemia, and a 5-year follow up of rituximab-venetoclax in relapsed/refractory CLL

25 augusti 2022 | 20 min

Stroke in hereditary TTP, and germline DDX41 variants as risk factors and prognostic markers in myeloid neoplasms

18 augusti 2022 | 21 min

Cost effectiveness of first-line daratumumab in MM, base-edited CAR T cells for T-ALL, and the role of SETBP1 mutations in chronic neutrophilic leukemia

11 augusti 2022 | 19 min

Immune thrombocytopenia and adenoviral SARS-COV2 vaccines, genomics, and a risk assessment model of anti-CD19 CAR T-cell treatment outcomes in lymphoma

4 augusti 2022 | 21 min

Naturally selected CD7 CAR T cell therapy for T-lineage malignancies, CD4+ T cell exhaustion and PD-L1 inhibition in B-ALL, and tPA-induced phosphorylation of occludin in stroke

28 juli 2022 | 18 min

Role of PIEZO1 in leukocyte extravasation, CD8+ T-cell activation in macrophage activation syndrome, and ABO O blood group as a novel risk factor for HIT

21 juli 2022 | 21 min

Long-term ibrutinib-rituximab vs FCR in CLL, procoagulant platelet sentinels in prevention of inflammatory bleeding, and new SERPINC1 variants in thrombophilia

14 juli 2022 | 19 min

Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-directed immunotherapies.

7 juli 2022 | 22 min

Overcoming CAR T cell resistance in myeloma, why anti-CCR4 antibody therapy in CTCL sometimes fails, and corticosteroids increase risk of VOE in sickle disease

30 juni 2022 | 19 min

Salvage therapy with NICE for Hodgkin lymphoma, BMP2/SMAD pathway activation in leukemic transformation, and the role of zinc in T-cell reconstitution after HSCT

23 juni 2022 | 19 min

MRD and post-transplant outcomes in older AML patients, enhancer hijacking in a novel high-risk B-other ALL subtype, and ruxolitinib in pediatric HLH

16 juni 2022 | 20 min

Anti-PF4 antibodies after Covid vaccination, CAR T-cell therapy for CNS leukemia, and advances in Diamond-Blackfan anemia

9 juni 2022 | 21 min

Fixed-duration ibrutinib + venetoclax for CLL, aryl hydrocarbon receptor in idiopathic pneumonia syndrome, and VWF propeptide and multimerization

2 juni 2022 | 22 min

HEATR3 variants as a new cause of Diamond-Blackfan anemia, zanubrutinib in mantle cell lymphoma, and HMGB1 inhibits Epo signaling in anemia of inflammation

26 maj 2022 | 20 min

HLA-DQ heterodimers and transplantation, the genomic landscape of LGL leukemia, and an updated classification of hemochromatosis

19 maj 2022 | 22 min

Role of macrophage NOX2 in alveolar homeostasis, hydroxyurea versus peginterferon alfa-2a in high-risk PV and ET, and the emerging PV treatment landscape

12 maj 2022 | 21 min

Microbiome and CD4 T-cell recovery after allogeneic HCT, and a paradigm shift to CAR T-cells in the second line for large B-cell lymphoma?

5 maj 2022 | 20 min

Canakinumab in SCA, antigen-specific donor T-cells to prevent post-transplant relapse in ALL, and nasopharyngeal mucosal immunity defects in transplanted SCID patients

28 april 2022 | 20 min

Timing (and utility) of CNS prophylaxis in DLBCL, Apollo deficiency in a bone marrow failure syndrome, and GATA1 mutants in congenital anemia

21 april 2022 | 17 min

Obinutuzumab plus lenalidomide in advanced follicular lymphoma, mechanisms of anemia in children with malaria, and granulocyte microvesicles for septic shock

14 april 2022 | 19 min

Structural racism and AML survival, promoter competition and hemoglobin switching, and CAR T-cell therapy and high-risk cytogenetics in ALL

7 april 2022 | 18 min

Targeting the PBX1-FOXM1 axis in myeloma, SF3B1 mutations in MDS, and pulmonary artery hypertension-associated mortality in β-thalassemia patients

31 mars 2022 | 19 min

Novel high-risk subtypes in adult B-ALL, Liso-cel CAR-T therapy in CLL, and liquid biopsies in large B-cell lymphomas

24 mars 2022 | 18 min

Effective treatments for kaposiform hemangioendothelioma, causes of vascular dysfunction in sickle cell patients, and better strategies to select therapy in older adults with AML

17 mars 2022 | 19 min

COVID-19 vaccination in patients with blood cancers and recalibrating the HLA barrier in haploidentical stem cell transplantation

10 mars 2022 | 19 min

Cell therapy options for chemo-sensitive DLBCL, PIGA mutations in a novel subtype of hemochromatosis, and triplet combination therapy in high-risk CLL

3 mars 2022 | 21 min

Germline predisposition mutations in AML, a new way to resolve NETs, and venetoclax and BAX mutations in normal myeloid cells of CLL patients

24 februari 2022 | 19 min

Ovarian reserve in sickle cell anemia, genomic landscape of adult T-cell leukemia/lymphoma, and a new prognostic index for HLH-associated heme malignancies

17 februari 2022 | 20 min

Role of HBO1 in HSC function, robust MRD analysis in multiple myeloma, and cardiac ferroptosis in sickle cell disease

10 februari 2022 | 16 min

The ARID3A transcription factor suppresses leukemia, a COVID-19 booster shot benefits CLL patients, and advances in the genetics of congenital neutropenia

3 februari 2022 | 20 min

Sustained MRD negativity & outcomes in myeloma, therapeutic targeting of VWF in TTP, and improving CAR T-cells in CLL with PI3 kinase inhibition

28 januari 2022 | 20 min

Does route of CNS prophylaxis for DLBCL matter?, the connection between CHIP and COPD, and ATRA plus low-dose rituximab in ITP

20 januari 2022 | 22 min

A spectrum of ALK-positive histiocytosis, and metabolites as biomarkers for GvHD diagnosis and risk assignment

13 januari 2022 | 15 min

Long-term outcomes in severe aplastic anemia, cytoprotective effects of factor VIIa, and the role of IL-1 in hematopoietic stem cell ageing

6 januari 2022 | 21 min

CRISPR cure for XMEN disease?, JAK inhibition in T-cell lymphomas, and intracranial hemorrhage in hemophilia

30 december 2021 | 20 min

Antigen presentation by platelet extracellular vesicles, fibril-reactive monoclonal antibody therapy for AL amyloidosis, and targeting gasdermin D in sepsis

23 december 2021 | 19 min

Mesenchymal stromal cells in SCD, CAR T-cell-mediated hematotoxicity in B-cell lymphoma, and dual cytokine blockade in GVHD

16 december 2021 | 18 min

PROTACs for JAKs in CRLF2-rearranged ALL, risk stratification in Down syndrome-associated leukemia, and how losing sialic acid activates immune cells in ITP

9 december 2021 | 19 min

Belumosudil for chronic GVHD, mechanistic insights into VITT, and factors driving molecular response in IFNα-treated MPNs

2 december 2021 | 20 min

Post-vaccination COVID-19 in patients with hematologic malignancies

1 december 2021 | 22 min

Asciminib versus bosutinib in CML; dopamine signaling and hematopoietic stem cells; complement factor C5 and VTE risk

25 november 2021 | 21 min

Danicopan add-on therapy in PNH, neural networks to identify bone marrow cells, and RNA editome and hematopoiesis

18 november 2021 | 18 min

Machine learning in classification of AML, aging bone marrow in leukemia, and treating bleeding disorders of unknown cause

11 november 2021 | 19 min

Anti-CD36-antibody therapy of neonatal alloimmune thrombocytopenia, costs of hemophilia B gene therapy, and insights into erythroid maturation

4 november 2021 | 18 min

Genetic risks for CMV after BMT, multiplex gene editing to reactivate HbF, and rewiring plasma cells in light chain amyloidosis and myeloma

28 oktober 2021 | 20 min

Omidubicel vs standard umbilical cord blood transplant, CAR T-cell associated lymphomas, and CD63 and ferritin export

21 oktober 2021 | 20 min

Iron homeostasis and anemia of inflammation in TB, and long-term outcomes of gene therapy in adenosine deaminase-deficient SCID patients

14 oktober 2021 | 15 min

Immune megakaryocytes, PD1 deletions in CTCL, and COVID-19 vaccine and VITT

7 oktober 2021 | 19 min

Inhibition of P-selectin as an anticoagulant, prognostic implications of CEBPA mutations in AML, and treating sickle cell disease with voxelitor

30 september 2021 | 15 min

Caution on JAK inhibitors in HLH, CD44 loss sensitizes AML to venetoclax, and new insights on cell cycle control in Richter transformation

23 september 2021 | 15 min

Improved risk assessment in adult BCR-ABL1-negative B-ALL, value of clone metrics in clonal cytopenias, a placental protease generates a peptide to inhibit NET formation

16 september 2021 | 18 min

Fixed-duration venetoclax in relapsed CLL, differing effects of invariant NK T cells, and under recognition of rare TERT variants in MDS

9 september 2021 | 23 min

Activated BCL11B in acute leukemias, SARS-CoV-2 antibody responses in lymphoma patients receiving B-cell therapies, and PD-L1 in neutrophil apoptosis and tissue inflammation

2 september 2021 | 18 min

Review Series on Mechanisms of Hematologic Malignancies

26 augusti 2021 | 28 min

IFN-λ therapy for GvHD, mechanism of decitabine in ITP, and TET2 mutations in chronic NK-LGL leukemia

26 augusti 2021 | 18 min

Choosing chemotherapy for older patients with AML, the role of the microenvironment in pediatric ALL, and efficacy of thrombopoietin receptor agonists in elderly patients with ITP

19 augusti 2021 | 18 min

Brentuximab plus nivolumab in refractory/relapsed Hodgkin lymphoma, the signature of aging hematopoietic stem cells, and hepatocyte neogenin in iron homeostasis

12 augusti 2021 | 16 min

Latest Research on the Intensity of AML Therapy in Older Patients, Platelets and T cell Activity in Sepsis, and Genotyping for CNS Lymphoma

5 augusti 2021 | 19 min

Vaccine-induced Immune Thrombotic Thrombocytopenia

29 juli 2021 | 18 min

Latest research in post-transplant cyclophosphamide in matched unrelated versus haploidentical donors, outcomes in patients with AITL, and high molecular weight kininogen in acetaminophen-induced liver injury

22 juli 2021 | 17 min

Latest research in thrombosis in pediatric COVID-19, prognostic tool for very early stage CLL, and frontline treatment for newly diagnosed myeloma

15 juli 2021 | 18 min

Latest Research: Immunity to CMV, lymphoma microenvironment, and tPA induced bleeding

8 juli 2021 | 15 min

Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas

Senaste avsnitt

Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleeding

Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia

A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse

Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor

Review series on mantle cell lymphoma

Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas

A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes

An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM

Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in a

Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets

A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset

Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

How I Treat Series on Geriatric Hematology

Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance

New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE

How I Treat Transfusion Medicine (part 2)

Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma

How I Treat Transfusion Medicine (part 1)

Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT

Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease

Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature

Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy

How I Treat Myeloproliferative Neoplasms

The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL

Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma

Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL

Blood Bonus Episode: What is a Blood group?

Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait

Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis

Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL

Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk

Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal antibodies

Review Series on a Quarter Century of TKIs in CML

A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes

Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor

Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor

First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia

Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex

Review Series on Globin Disorders

Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma

Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk

Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

Unravelling follicular lymphoma subtypes; stroke rate trends in sickle cell disease; procoagulant platelet activation promotes venous thrombosis

Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma

Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH

Review Series on T-Cell Lymphoma

Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets

Exploring the ecosystem of extramedullary myeloma; role of ruxolitinib for pediatric acute GvHD; “YAP”-ing about YAP1 and thrombopoiesis in ITP

First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia

Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML

Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis

Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia

Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS

A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT

Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis

Transplant outcomes in pediatric Fanconi anemia; hepatic Foxo1 regulates iron homeostasis; clinical networks improve APL outcomes in Latin America

CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and NPM1-altered leukemias

TCR-T cells for post-HCT leukemia recurrence; platelets are the predominant source of procoagulant membranes in hemostasis; BR + R maintenance for MCL

Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors

Review Series on Factor XI

Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL

Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML

Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD

Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity

Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism

Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT

Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of <em>SOX11</em> expression to EBV-negative Burkitt lymphomas

Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome

Review Series on Oncogenic Signaling and Immune Evasion in Hematologic Malignancies

GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL

Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease

A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy

Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma

Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML

Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia